List volumes - List articles in this issue


Prevention of Ulcerative Lesions by Episodic Treatment of Recurrent Herpes Labialis: A Literature Review

doi: 10.2340/00015555-0806


There are substantial difficulties involved in carrying out clinical studies of recurrent herpes labialis, since the disease has a rapid onset, short-lasting viral shedding period and is rapidly self-healing. The aim of this paper was to critically assess published reports of episodic treatment of herpes labialis and to review biological and methodological problems involved in such studies. Limited, but statistically significant, results have been shown with topical antivirals, such as acyclovir and penciclovir, improving healing times by approximately 10%. Orally administrated antivirals, such as valaciclovir and famciclovir, have subsequently found clinical use. However, these two oral medications have different profiles in phase 3 studies. Famciclovir showed additional improve­ment of efficacy in terms of lesion healing time, but no effect on prevention of ulcerative lesions, while valaciclovir appeared to have similar efficacy to that of acy­clovir cream on lesion healing, but some additional efficacy with respect to prevention of ulcerative lesions. A formulation of acyclovir/hydrocortisone showed further improvement in prevention of ulcerative lesions, while retaining efficacy with respect to lesion healing.


Johan Harmenberg, Bo Öberg, Spotswood Spruance


  • Spruance SL. The natural history of recurrent oral-facial herpes simplex virus infection. Semin Dermatol 1992; 11: 200–206.
  • Wald A, Ericsson M, Krantz E, Selke S, Corey L. Oral shedding of herpes simplex virus type 2. Sex Transm Infect 2004; 80: 272–276.
  • Spruance SL. Herpes simplex labialis. In: Sacks SL, Straus SE, Whitley RJ, editors. Clinical management of herpes viruses. Amsterdam, Washington DC: IOS Press; 1995, p. 3–42.
  • Spruance SL, Overall JC, Jr, Kern ER, Krueger GG, Pliam V, Miller W. The natural history of recurrent herpes simplex labialis: implications for antiviral therapy. N Engl J Med 1977; 297: 69–75.
  • Morrel EM, Spruance SL, Goldberg DI, Iontophoretic Acyclovir Cold Sore Study G. Topical iontophoretic administration of acyclovir for the episodic treatment of herpes labialis: a randomized, double-blind, placebo-controlled, clinic-initiated trial. Clin Infect Dis 2006; 43: 460–467.
  • Ross S. A first course in probability. Upper Saddle River, New Jersey, USA: Pearson Education, Inc., 2006.
  • Löwhagen GB, Bonde E, Eriksson B, Nordin P, Tunbäck P, Krantz I. Self-reported herpes labialis in a Swedish population. Scand J Infect Dis 2002; 34: 664–667.
  • Hellgren L. The prevalence of some skin disease and joint disease in total populations in different areas of Sweden. Proc Northern Dermatol Soc 1962: 155–162.
  • Axell T, Liedholm R. Occurrence of recurrent herpes labialis in an adult Swedish population. Acta Odontol Scand 1990; 48: 119–123.
  • Reichart PA. Oral mucosal lesions in a representative cross-sectional study of aging Germans. Community Dent Oral Epidemiol 2000; 28: 390–398.
  • Hatherley LI, Hayes K, Hennessy EM, Jack I. Herpes virus in an obstetric hospital: I: Herpetic eruptions. Med J Aust 1980; 2: 205–208.
  • Spruance SL, Rea TL, Thoming C, Tucker R, Saltzman R, Boon R. Penciclovir cream for the treatment of herpes simplex labialis. A randomized, multicenter, double-blind, placebo-controlled trial. Topical Penciclovir Collaborative Study Group. JAMA 1997; 277: 1374–1379.
  • Ship II, Morris AL, Durocher RT, L.W. B. Recurrent aphthous uncelations and recurrent herpes labialis in a professional school student population. I. Experience. Oral Surg Oral Med Oral Pathol 1960; 13: 1191–1202.
  • Ship II, Brightman VJ, Laster LL. The patient with recurrent aphthous ulcers and the patient with recurrent herpes labialis: a study of two population samples. J Am Dent Assoc 1967; 75: 645–654.
  • Young TB, Rimm EB, D’Alessio DJ. Cross-sectional study of recurrent herpes labialis. Prevalence and risk factors. Am J Epidemiol 1988; 127: 612–625.
  • Grout P, Barber VE. Cold sores-an epidemiological survey. J R Coll Gen Pract 1976; 26: 428–434.
  • Embil JA, Stephens RG, Manuel FR. Prevalence of recurrent herpes labialis and aphthous ulcers among young adults on six continents. Can Med Assoc J 1975; 113: 627–630.
  • Hull C, Harmenberg J, Arlander E, Aoki F, Darpo B, Levin M, et al. Episodic treatment with topical ACV/hydrocortisone (Lipsovir®) prevents cold sores: a randomized, double-blind, patient-initiated clinical trial. Abstract, 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 12–15, San Fransisco, California, USA, 2009.
  • Spruance SL, Jones TM, Blatter MM, Vargas-Cortes M, Barber J, Hill J, et al. High-dose, short-duration, early valacyclovir therapy for episodic treatment of cold sores: results of two randomized, placebo-controlled, multicenter studies. Antimicrob Agents Chemother 2003; 47: 1072–1080.
  • Elish D, Singh F, Weinberg JM. Therapeutic options for herpes labialis, II: Topical agents. Cutis 2004; 74: 35–40.
  • Elish D, Singh F, Weinberg JM. Therapeutic options for herpes labialis, I: Oral agents. Cutis 2004; 74: 31–34.
  • Moomaw MD, Cornea P, Rathbun RC, Wendel KA. Review of antiviral therapy for herpes labialis, genital herpes and herpes zoster. Expert Rev Anti Infect Ther 2003; 1: 283–295.
  • Imanidis G, Song WQ, Lee PH, Su MH, Kern ER, Higuchi WI. Estimation of skin target site acyclovir concentrations following controlled (trans)dermal drug delivery in topical and systemic treatment of cutaneous HSV-1 infections in hairless mice. Pharm Res 1994; 11: 1035–1041.
  • Mehta SC, Afouna MI, Ghanem AH, Higuchi WI, Kern ER. Relationship of skin target site free drug concentration (C*) to the in vivo efficacy: an extensive evaluation of the predictive value of the C* concept using acyclovir as a model drug. J Pharm Sci 1997; 86: 797–801.
  • Physicians’ Desk Reference. Thomson PDR Electronic Library, version 7.0.308a, Thomson Reuters, Montvale, New Jersey, USA, 2009.
  • Spruance SL, Nett R, Marbury T, Wolff R, Johnson J, Spaulding T. Acyclovir cream for treatment of herpes simplex labialis: results of two randomized, double-blind, vehicle-controlled, multicenter clinical trials. Antimicrob Agents Chemother 2002; 46: 2238–2243.
  • Spruance SL, Bodsworth N, Resnick H, Conant M, Oeuvray C, Gao J, et al. Single-dose, patient-initiated famciclovir: a randomized, double-blind, placebo-controlled trial for episodic treatment of herpes labialis. J Am Acad Dermatol 2006; 55: 47–53.
  • Freeman DJ, Sheth NV, Spruance SL. Failure of topical acyclovir in ointment to penetrate human skin. Antimicrob Agents Chemother 1986; 29: 730–732.
  • Freeman DJ, Spruance SL. Efficacy of topical treatment for herpes simplex virus infections: predictions from an index of drug characteristics in vitro. J Infect Dis 1986; 153: 64–70.
  • Spruance SL, Freeman DJ, Sheth NV. Comparison of foscarnet cream, acyclovir cream, and acyclovir ointment in the topical treatment of experimental cutaneous herpes simplex virus type 1 infection. Antimicrob Agents Chemother 1986; 30: 196–198.
  • Padula C, Sartori F, Marra F, Santi P. The influence of iontophoresis on acyclovir transport and accumulation in rabbit ear skin. Pharm Res 2005; 22: 1519–1524.
  • Volpato NM, Nicoli S, Laureri C, Colombo P, Santi P. In vitro acyclovir distribution in human skin layers after transdermal iontophoresis. J Control Release 1998; 50: 291–296.
  • Alenius S, Berg M, Broberg F, Eklind K, Lindborg B, Öberg B. Therapeutic effects of foscarnet sodium and acyclovir on cutaneous infections due to herpes simplex virus type 1 in guinea pigs. J Infect Dis 1982; 145: 569–573.
  • Richards DM, Carmine AA, Brogden RN, Heel RC, Speight TM, Avery GS. Acyclovir. A review of its pharmacodynamic properties and therapeutic efficacy. Drugs 1983; 26: 378–438.
  • McKeough MB, Spruance SL. Comparison of new topical treatments for herpes labialis: efficacy of penciclovir cream, acyclovir cream, and n-docosanol cream against experimental cutaneous herpes simplex virus type 1 infection. Arch Dermatol 2001; 137: 1153–1158.
  • Poli G, Dall’Ara P, Binda S, Santus G, Poli A, Cocilovo A, et al. Value of the dorsal cutaneous guinea pig model in selecting topical antiviral formulations for the treatment of recurrent herpes simplex type 1 disease. Arzneimittelforschung 2001; 51: 433–438.
  • Corey L, Benedetti JK, Critchlow CW, Remington MR, Winter CA, Fahnlander AL, et al. Double-blind controlled trial of topical acyclovir in genital herpes simplex virus infections. Am J Med 1982; 73: 326–334.
  • Corey L, Nahmias AJ, Guinan ME, Benedetti JK, Critchlow CW, Holmes KK. A trial of topical acyclovir in genital herpes simplex virus infections. N Engl J Med 1982; 306: 1313–1319.
  • Raborn GW, Martel AY, Lassonde M, Lewis MA, Boon R, Spruance SL, et al. Effective treatment of herpes simplex labialis with penciclovir cream: combined results of two trials. J Am Dent Assoc 2002; 133: 303–309.
  • Reichman RC, Badger GJ, Guinan ME, Nahmias AJ, Keeney RE, Davis LG, et al. Topically administered acyclovir in the treatment of recurrent herpes simplex genitalis: a controlled trial. J Infect Dis 1983; 147: 336–340.
  • Spruance SL, Crumpacker CS. Topical 5 percent acyclovir in polyethylene glycol for herpes simplex labialis. Antiviral effect without clinical benefit. Am J Med 1982; 73: 315–319.
  • Awan AR, Harmenberg J, Kristofferson A, Field HJ. Herpes simplex virus zosteriform lesions with adoptive transfer of immune cells: a murine model which mimics human recurrent disease. Antiviral Res 1998; 38: 43–53.
  • Awan AR, Harmenberg J, Flink O, Field HJ. Combinations of antiviral and anti-inflammatory preparations for the topical treatment of herpes simplex virus assessed using a murine zosteriform infection model. Antivir Chem Chemother 1998; 9: 19–24.
  • Harmenberg JG, Awan AR, Alenius S, Ståhle L, Erlandsson AC, Lekare G, et al. ME-609: a treatment for recurrent herpes simplex virus infections. Antivir Chem Chemother 2003; 14: 205–215.
  • Spruance SL, McKeough MB. Combination treatment with famciclovir and a topical corticosteroid gel versus famciclovir alone for experimental ultraviolet radiation-induced herpes simplex labialis: a pilot study. J Infect Dis 2000; 181: 1906–1910.
  • Evans TG, Bernstein DI, Raborn GW, Harmenberg J, Kowalski J, Spruance SL. Double-blind, randomized, placebo-controlled study of topical 5% acyclovir-1% hydrocortisone cream (ME-609) for treatment of UV radiation-induced herpes labialis. Antimicrob Agents Chemother 2002; 46: 1870–1874.
  • Hull C, McKeough M, Sebastian K, Kriesel J, Spruance S. Valacyclovir and topical clobetasol gel for the episodic treatment of herpes labialis: a patient-initiated, double-blind, placebo-controlled pilot trial. J Eur Acad Dermatol Venereol 2009; 23: 263–267.
  • Magnusson BM, Cross SE, Winckle G, Roberts MS. Percutaneous absorption of steroids: determination of in vitro permeability and tissue reservoir characteristics in human skin layers. Skin Pharmacol Physiol 2006; 19: 336–342.
  • Pelchrzim R, Weigmann HJ, Schaefer H, Hagemeister T, Linscheid M, Shah VP, et al. Determination of the formation of the stratum corneum reservoir for two different corticosteroid formulations using tape stripping combined with UV/VIS spectroscopy. J Dtsch Dermatol Ges 2004; 2: 914–919.
  • Turpeinen M. Absorption of hydrocortisone from the skin reservoir in atopic dermatitis. Br J Dermatol 1991; 124: 358–360.
  • Vickers CF. Stratum corneum reservoir for drugs. Adv Biol Skin 1972; 12: 177–189.
  • Spruance SL, Hill J. Clinical significance of antiviral therapy for episodic treatment of herpes labialis: exploratory analyses of the combined data from two valaciclovir trials. J Antimicrob Chemother 2004; 53: 703–707.
  • Related articles

    There are no related articles.

    Share with your friends



    Full text



    There is no supplementary for this article.

    Print information

    Volume 90, Issue 2

    DOI: 10.2340/00015555-0806

    Pages: 122-130

    View at PubMed